Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.

Blood advances - 25 Feb 2020

Lee Lynn H, Krupski Christa, Clark Jason, Wunderlich Mark, Lorsbach Robert B, Grimley Michael S, Burwinkel Matthew, Nelson Adam, Kumar Ashish R

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a rare hematologic neoplasm characterized by a clonal proliferation of Langerhans-like cells. Genomic profiling has identified recurrent somatic activating mutations in the mitogen-activated protein kinase pathway, which are targetable by small-molecule inhibitors. However, key questions such as the curative potential of targeted therapy and the cell of origin remain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Heterografts

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Histiocytosis, Langerhans-Cell

Share to Infant

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 32092141
DOI: 10.1182/bloodadvances.2019032367
PMCID: PMC7042980

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.PMID 32092141Read ↗

Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.Semantic proximity Read ↗

Recent advances in the understanding of Langerhans cell histiocytosisSemantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

Clinical and prognostic features of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Histiocyte Society blueprint for Langerhans cell histiocytosis research: from cell-of-origin to a more comprehensive cure.Semantic proximity Read ↗

Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.Semantic proximity Read ↗

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read ↗

BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy.Semantic proximity Read ↗

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity Read ↗

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.Semantic proximity Read ↗

Dabrafenib or trametinib in pediatric Langerhans cell histiocytosis with bone lesions: a retrospective efficacy and safety study.Semantic proximity Read ↗

[Pathophysiology and treatment of adult Langerhans cell histiocytosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.